Covalent drugs have emerged as a groundbreaking modality for improving the affinity, potency, and duration of action of molecularly targeted inhibitors. Prof. ... Read more

A major challenge in developing viral-based therapies, such as gene therapies, CAR-T cell immunotherapy, and oncolytic virotherapy, is that the most efficient vectors and viruses are not specific, preventing their direct administration to the patient. Prof. ... Read more

Enveloped viruses pose significant health risks and lack effective treatments. Inhibiting viral membrane fusion, a crucial step in infection, holds promise for antiviral drug development. Dr. ... Read more

Chimeric Antigen Receptor (CAR)-T Cell Therapy is a personalized treatment for cancer in which the patient's T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. ... Read more

MAPP (Mass Spectrometry Analysis of Proteolytic Peptides) is a groundbreaking technology that isolates and identifies proteins actively degraded by the proteasome, offering an unparalleled and direct view of the "active degradome." This innovative approach provides a sensitive an ... Read more